MariTime CV
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants Living with Overweight or Obesity and Atherosclerotic Cardiovascular Disease
- Stage
- inclusie
- Medicine
- Meridebart Cafraglutide
- Population
- ASCVD
- Phase
- III
- First Patient In
- 15 October 2025
- Last Patient In
- 29 March 2027
- Last Patient Last Visit
- 29 September 2030
Inclusion period, 485 days remaining
National Lead
prof. dr. J.H. Cornel
Cardioloog
Study Director
drs. H.P. Swart
Cardioloog
Office Contact
